Topic: 23andme Bankruptcy

Genetic testing company 23andMe has filed for bankruptcy protection following years of financial challenges, leading CEO Anne Wojcicki to resign. The California Attorney General has urged customers to request the deletion of their data and the destruction of genetic samples to prevent them from being sold during the liquidation process. This development follows decade-long warnings from privacy advocates regarding the long-term security of personal DNA databases.

The financial collapse of 23andMe is analyzed, with its stock losing 99.9% of its value and its board of directors resigning. Concerns are raised about the fate of the genetic data of 14 million customers, which is not protected by HIPAA. The data is currently being shared with GlaxoSmithKline (GSK) for pharmaceutical research, leading to fears that "anonymous" genetic information could eventually be weaponized or sold.